West Pharma Q1 Net Income Jumps 54% on 21% Revenue Surge
WST sits 42% above its 52-week low of $199.89.
Summary
West Pharmaceutical Services reported robust first-quarter 2026 results, with net income increasing to $138.8 million ($1.92 EPS) from $89.8 million ($1.23 EPS) year-over-year, representing a 54.5% jump in net income. Revenue also saw a significant 21.0% increase, reaching $844.9 million. The company provided Q2 revenue guidance of $830 million to $850 million and full-year EPS guidance of $8.40 to $8.75, alongside full-year revenue guidance of $3.295 billion to $3.350 billion. This comprehensive earnings report provides a positive update on the company's operational performance, building on the previously released Q2 sales guidance. The strong growth in both top and bottom lines indicates healthy demand and execution, which should be viewed favorably by the market. Traders will now focus on the company's ability to maintain this momentum and achieve its updated full-year targets.
At the time of this announcement, WST was trading at $283.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $19.8B. The 52-week trading range was $199.89 to $322.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.